GoAI
Get started
PMGC Holdings Inc. logo

PMGC Holdings Inc.

ELAB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.66

+$0.56 · +9.18%

Aug 21, 4:00 PM ET

ELAB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

24

Weakening

Sentiment

55

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $6.66

52-week range

Current $6.66

Open
$6.60
Previous close
$6.10
Volume
204.02K
Market cap
3.03M USD
50-day average
$10.6984
-37.75% below average
200-day average
$249.19
-97.33% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
133.94K USD
EV / EBITDA
-0.02×
Earnings yield
-266.60%
Free cash flow yield
-220.73%

Profitability & efficiency

Return on equity
-98.35%
Return on assets
-59.90%
Return on invested capital
-70.17%

Financial health

Current ratio
1.74×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends9573%-28428%-66428%-104429%Gross margin, FY2021: -244.01%Gross margin, FY2022: 58.37%Gross margin, FY2023: 66.25%Gross margin, FY2024: 72.84%Gross margin, FY2025: 12.68%Operating margin, FY2021: -94928.66%Operating margin, FY2022: -233.37%Operating margin, FY2023: -66.62%Operating margin, FY2024: -75.65%Operating margin, FY2025: -1250.11%Net margin, FY2021: -94889.84%Net margin, FY2022: -234.94%Net margin, FY2023: -251.17%Net margin, FY2024: -253.14%Net margin, FY2025: -1306.28%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -244.01%. Gross margin FY2022 58.37%. Gross margin FY2023 66.25%. Gross margin FY2024 72.84%. Gross margin FY2025 12.68%. Operating margin FY2021 -94928.66%. Operating margin FY2022 -233.37%. Operating margin FY2023 -66.62%. Operating margin FY2024 -75.65%. Operating margin FY2025 -1250.11%. Net margin FY2021 -94889.84%. Net margin FY2022 -234.94%. Net margin FY2023 -251.17%. Net margin FY2024 -253.14%. Net margin FY2025 -1306.28%.

Income trends

Revenue

590.08K USD-76.08%

Operating income

−7.38M USD-295.20%

Net income

−7.71M USD-23.41%
Income trends across reported periods3.48M USD−585.33K USD−4.66M USD−8.73M USDRevenue, FY2021: 827 USDRevenue, FY2022: 766.28K USDRevenue, FY2023: 1.71M USDRevenue, FY2024: 2.47M USDRevenue, FY2025: 590.08K USDOperating income, FY2021: −785.06K USDOperating income, FY2022: −1.79M USDOperating income, FY2023: −1.14M USDOperating income, FY2024: −1.87M USDOperating income, FY2025: −7.38M USDNet income, FY2021: −784.74K USDNet income, FY2022: −1.8M USDNet income, FY2023: −4.3M USDNet income, FY2024: −6.25M USDNet income, FY2025: −7.71M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 827 USD. Revenue FY2022 766.28K USD. Revenue FY2023 1.71M USD. Revenue FY2024 2.47M USD. Revenue FY2025 590.08K USD. Operating income FY2021 −785.06K USD. Operating income FY2022 −1.79M USD. Operating income FY2023 −1.14M USD. Operating income FY2024 −1.87M USD. Operating income FY2025 −7.38M USD. Net income FY2021 −784.74K USD. Net income FY2022 −1.8M USD. Net income FY2023 −4.3M USD. Net income FY2024 −6.25M USD. Net income FY2025 −7.71M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue590.08K USD2.47M USD1.71M USD766.28K USD827 USD
Cost of goods sold515.27K USD670.2K USD578.02K USD318.97K USD2.85K USD
Gross profit74.81K USD1.8M USD1.13M USD447.31K USD−2.02K USD
Research and development147.01K USD104.65K USD426.24K USD228.75K USD123.63K USD
Selling, general, and administrative1.62M USD855.76K USD4.03M USD1.73M USD633.96K USD
Operating expenses7.45M USD3.66M USD5.42M USD2.24M USD783.04K USD
Interest income118.03K USD12.89K USD5.56K USD7.7K USD—
Interest expense547.13K USD735.2K USD19.53K USD2.63K USD—
Depreciation and amortization110.5K USD83.1K USD11.65K USD6.51K USD2.76K USD
Operating income−7.38M USD−1.87M USD−1.14M USD−1.79M USD−785.06K USD
Net income−7.71M USD−6.25M USD−4.3M USD−1.8M USD−784.74K USD

Company facts updated Aug 24, 2026.

ELAB news

globenewswire.com

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

Read source
globenewswire.com

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and…

Read source
globenewswire.com

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-o

Read source
globenewswire.com

PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement

Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization Company Reports…

Read source
globenewswire.com

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

NEWPORT BEACH, Calif. , July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company executing a precision manufacturing growth strategy…

Read source
globenewswire.com

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

PMGC Holdings Inc.

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 21, 2026

1:10

Stock split

Effective Mar 10, 2026

1:6

Stock split

Effective Jan 6, 2026

1:4

Stock split

Effective Sep 2, 2025

2:7

Stock split

Effective Mar 10, 2025

1:7

Stock split

Effective Nov 27, 2024

1:200

ELAB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ELAB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
15.39K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research ELAB

research.disclaimer